Chromatin, a developer of mini-chromosome technology, has completed a Series C financing round of $12.4m, led by Quantitative Financial Strategies and consisting of Malaysian Life Sciences Capital Fund, Burrill & Company, Venture Investors, Unilever Technology Ventures, Foragen Technology Ventures and Illinois Ventures.
In order to view premium content you need to be a Premium Subscriber. You can subscribe now to access premium online content.
Find out who else is a subscriber »
Become a Premium SubscriberIf you are already a NewNet subscriber please log in below.
Legals & Terms of Use • Privacy Policy
NewNet is a trading name of New Energy World Network Ltd, registered in England (No. 06695690).
Registered Office: Zetland House, 5-25 Scrutton St, London EC2A 4HJ
Content is © New Energy World Network (NewNet) 2008-2012